Cargando…

Correction: A Novel Diphenylthiosemicarbazide Is a Potential Insulin Secretagogue for Anti-Diabetic Agent

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5231920/ https://www.ncbi.nlm.nih.gov/pubmed/28081219 http://dx.doi.org/10.1371/journal.pone.0170430

Ejemplares similares

A Novel Diphenylthiosemicarbazide Is a Potential Insulin Secretagogue for Anti-Diabetic Agent
por: Sugawara, Kenji, et al.
Publicado: (2016)

Author Correction: Berberine is an insulin secretagogue targeting the KCNH6 potassium channel
por: Zhao, Miao-Miao, et al.
Publicado: (2021)

Author Correction: Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study
por: Ciresi, Alessandro, et al.
Publicado: (2018)

Hypolipidaemic and Insulin Secretagogue Activities of (R)-(−)-Carvone
por: Abbas, Manal Ahmad, et al.
Publicado: (2020)

Contribution of Mitochondria to Insulin Secretion by Various Secretagogues
por: Ježek, Petr, et al.
Publicado: (2022)

Interprofessional Continuous Glucose Monitoring for Underserved Adults with Type 2 Diabetes on Insulin or Secretagogues
por: Fasina, Ife, et al.
Publicado: (2021)

Antihyperglycemic and Insulin Secretagogue Activities of Abrus precatorius Leaf Extract
por: Umamahesh, Balekari, et al.
Publicado: (2016)

Berberine is an insulin secretagogue targeting the KCNH6 potassium channel
por: Zhao, Miao-Miao, et al.
Publicado: (2021)

Phytochemical Investigation of Lepionurus sylvestris Blume and Their Anti-Diabetes Effects via Anti-Alpha Glucosidase and Insulin Secretagogue Activities Plus Molecular Docking
por: Phoopha, Sathianpong, et al.
Publicado: (2023)

Circulating adipokines data associated with insulin secretagogue use in breast cancer patients
por: Wintrob, Zachary A.P., et al.
Publicado: (2016)

Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial
por: Lund, Søren S, et al.
Publicado: (2009)

Association Between Serious Hypoglycemia and Calcium-Channel Blockers Used Concomitantly With Insulin Secretagogues
por: Nam, Young Hee, et al.
Publicado: (2021)

Correction: novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs
por: Jiang, Pengfei, et al.
Publicado: (2014)

A Decade’s Progress in the Development of Molecular Imaging Agents Targeting the Growth Hormone Secretagogue Receptor
por: Childs, Marina D., et al.
Publicado: (2020)

Correction: A Novel Synthesized Sulfonamido-Based Gallate—JEZ-C as Potential Therapeutic Agents for Osteoarthritis
por: Wei, Shixiu, et al.
Publicado: (2019)

Correction: A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent
por: Thakar, Manjusha, et al.
Publicado: (2020)

Correction to: Anti-migraine agents from an immunological point of view
por: Assas, Mushref Bakri
Publicado: (2021)

Circulating growth factors data associated with insulin secretagogue use in women with incident breast cancer
por: Wintrob, Zachary A.P., et al.
Publicado: (2017)

Insulin secretagogue use and circulating inflammatory C–C chemokine levels in breast cancer patients
por: Wintrob, Zachary A.P., et al.
Publicado: (2017)

Dataset on granulopoiesis- and lymphopoiesis-stimulating cytokine levels in insulin secretagogue users with incident breast cancer
por: Wintrob, Zachary A.P., et al.
Publicado: (2017)

Correction: Genome-Wide Transcriptional Effects of the Anti-Cancer Agent Camptothecin
por: Veloso, Artur, et al.
Publicado: (2013)

Correction: Characterisation of Mesothelioma-Initiating Cells and Their Susceptibility to Anti-Cancer Agents
por: Pasdar, Elham Alizadeh, et al.
Publicado: (2016)

Human pulmonary macrophage-derived mucus secretagogue
Publicado: (1984)

Neuroprotective Actions of Ghrelin and Growth Hormone Secretagogues
por: Frago, Laura M., et al.
Publicado: (2011)

Is ghrelin a glucagon‐like peptide‐1 secretagogue?
por: Ueno, Hiroaki, et al.
Publicado: (2015)

Correction to: MYL1501D Insulin Glargine: A Review in Diabetes Mellitus
por: Hoy, Sheridan M.
Publicado: (2020)

Correction to: Insulins for the long term management of diabetes mellitus in dogs: a review
por: Shiel, Robert E., et al.
Publicado: (2022)

Author Correction: Development of a novel anti-hepatitis B virus agent via Sp1
por: Hayakawa, Michiyo, et al.
Publicado: (2020)

Targeted intestinal delivery of incretin secretagogues—towards new diabetes and obesity therapies
por: Gribble, Fiona M., et al.
Publicado: (2018)

Correction: Biological evaluation of pyrazolyl-urea and dihydro-imidazo-pyrazolyl-urea derivatives as potential anti-angiogenetic agents in the treatment of neuroblastoma
por: Marengo, Barbara, et al.
Publicado: (2023)

TH1 and TH2 cytokine data in insulin secretagogues users newly diagnosed with breast cancer
por: Wintrob, Zachary A.P., et al.
Publicado: (2017)

Glinide, but Not Sulfonylurea, Can Evoke Insulin Exocytosis by Repetitive Stimulation: Imaging Analysis of Insulin Exocytosis by Secretagogue-Induced Repetitive Stimulations
por: Aoyagi, Kyota, et al.
Publicado: (2009)

Long-Term Effectiveness and Safety of Once Weekly Dulaglutide as Add-on to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
por: Mirabelli, Maria, et al.
Publicado: (2021)

Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
por: Rayer, Cassandra, et al.
Publicado: (2023)

Correction: A novel small molecule agent displays potent anti-myeloma activity by inhibiting the JAK2-STAT3 signaling pathway
por: Zhang, Zubin, et al.
Publicado: (2016)

Correction to: Aconitum lycoctonum L. (Ranunculaceae) mediated biogenic synthesis of silver nanoparticles as potential antioxidant, anti-infammatory, antimicrobial and antidiabetic agents
por: Khan, Zia ur Rehman, et al.
Publicado: (2023)

Correction to: The basal to total insulin ratio in outpatients with diabetes on basal-bolus regimen
por: Castellano, Elena, et al.
Publicado: (2018)

Expression Profiling of Human Basophils: Modulation by Cytokines and Secretagogues
por: MacGlashan, Donald
Publicado: (2015)

Growth Hormone Secretagogues and the Regulation of Calcium Signaling in Muscle
por: Bresciani, Elena, et al.
Publicado: (2019)

Binding Domain Characterization of Growth Hormone Secretagogue Receptor
por: Sun, Yuxiang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4b3k6u03p68ep6avsqlr82th8g